Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast ca...
Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer ( Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom )
17 Sep 2021
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or local...
Prof Thomas Powles - Queen Mary University of London, London, UK
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )
17 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )
17 Sep 2021
Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pl...
Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland
Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma ( Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland )
17 Sep 2021
OncoAlert and ecancer - ESMO 2021 preview
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 preview ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
17 Sep 2021
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethaso...
Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )
14 Sep 2021
Multidisciplinary management of ovarian germ cell tumours - a single institution...
Dr Sandip Ganguly - Tata Medical Center, Kolkata, India
Multidisciplinary management of ovarian germ cell tumours - a single institutional study from India ( Dr Sandip Ganguly - Tata Medical Center, Kolkata, India )
14 Sep 2021
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...
Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )
14 Sep 2021
Should every transplant eligible NDMM patient receive a transplant?
Prof Morie Gertz - Mayo Clinic, Rochester, USA
Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )
14 Sep 2021
Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )
10 Sep 2021
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-ta...
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )
10 Sep 2021
Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma patie...
Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic
Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma patients ( Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic )
10 Sep 2021